Lyme Disease Market Summary
Lyme disease, also called Lyme borreliosis, is an infectious illness caused primarily by the bacterium Borrelia burgdorferi and, in rare cases, Borrelia mayonii, transmitted to humans through the bite of infected blacklegged ticks. There is a gender disparity in the incidence of Lyme disease, with men being more likely to be affected than women. There are no vaccines currently being marketed for Lyme disease, and there is now a greater demand for Lyme disease vaccines due to the rise in infections in the US and Europe, arising from factors such as climate change. Alongside a predominant drive in prevention by various leading names, Moderna’s recent interest in the condition raises the prospect of additional prophylactic options over the longer term.
The US FDA has not approved any therapies specifically indicated for Lyme disease; instead, treatment relies on antibiotics approved for other bacterial infections that are commonly used off-label to manage the condition. Key emerging therapies for Lyme disease include VLA15 (Valneva and Pfizer), TP-05 (Tarsus Pharmaceuticals, Inc.), mRNA-1982 and mRNA-1975 (Moderna), and others. In April 2025, researchers engineered a modified version of the Lyme bacterial protein CspZ, which in preclinical studies triggered a strong immune response and showed potential as a next-generation vaccine target; the breakthrough, published in Nature Communications, could pave the way for the first effective human Lyme disease vaccine.
DelveInsight’s “Lyme Disease Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth analysis of Lyme disease, market, and clinical development in Lyme disease, along with historical and forecasted epidemiology and market data, and a detailed analysis of Lyme disease market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted Lyme disease market size from 2020 to 2034 in the 7MM, along with current treatment practices/algorithms and unmet medical needs.
Explore DelveInsight’s Full Coverage on the Lyme Disease Market
Lyme Disease Overview
Lyme disease is the most common vector-borne illness in the U.S., caused by Borrelia burgdorferi in North America and Borrelia afzelii or Borrelia garinii in Europe and Asia. It is transmitted through bites of infected black-legged ticks (Ixodes species), with the infection progressing from early localized disease with erythema migrans and flu-like symptoms to disseminated and late stages that may affect the joints, nervous system, or heart. Diagnosis relies on clinical features, exposure history, and serologic testing, with early antibiotic treatment (doxycycline, amoxicillin, or cefuroxime) preventing long-term complications. Most patients recover fully, but delayed or inadequate therapy can cause persistent symptoms. Prevention centers on minimizing tick exposure through protective clothing, repellents, prompt removal, and habitat management.
Lyme Disease Diagnosis and Treatment Algorithm
The diagnosis of Lyme disease is established through an integrated assessment of clinical manifestations, most notably the pathognomonic erythema migrans rash, in conjunction with a history of potential exposure to Ixodes tick habitats. Given that tick bites frequently go unrecognized due to their minimal local symptoms, reliance on exposure risk is essential. Laboratory confirmation is achieved via a standardized two-tier serologic testing algorithm, wherein an initial enzyme immunoassay (EIA) or immunofluorescence assay (IFA) is followed by a confirmatory Western blot or equivalent immunoassay if results are positive or equivocal. Definitive diagnosis requires concordant results across both stages, ensuring high specificity and reducing false-positive outcomes.
Most cases of Lyme disease respond well to a 10–14 day course of antibiotics, with early treatment usually resulting in rapid and complete recovery. Commonly prescribed agents include doxycycline, amoxicillin, and cefuroxime axetil, with the choice of regimen guided by clinical presentation, patient age, allergy profile, pregnancy status, and other individual factors. Prompt diagnosis and timely initiation of therapy are critical to preventing progression to more severe disease. While routine antibiotic use after tick bites is not recommended, a single prophylactic dose of doxycycline may be considered in high-risk situations, such as bites acquired in areas of high Lyme disease prevalence, in line with established clinical guidelines and epidemiological context.
Lyme Disease Market Players
Lyme Disease companies include:
- Valneva
- Pfizer
- Tarsus Pharmaceuticals
- Moderna
- And Others.
Lyme Disease Epidemiology
The Lyme disease epidemiology chapter provides historical as well as forecasted epidemiology segmented as incident cases of Lyme disease, gender-specific incident cases of Lyme disease, age-specific incident cases of Lyme disease, and treatable cases of Lyme disease in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
Key Findings:
- The highest incidence of Borrelia infection causing Lyme disease is observed in children aged 5–15 years and adults over 50 years
- In the UK, the age distribution of Lyme disease shows the highest incidence in the 30–49 and 50–69 year age groups
- According to the Centers for Disease Control and Prevention, approximately 476,000 Americans are diagnosed and treated for Lyme disease each year, with at least a further 130,000 cases in Europe
- In Germany, the incidence of Lyme borreliosis was estimated at 37.2 cases per 100,000 person-years
- Of the reported Lyme disease cases, 58% occurred in men
- According to the Infectious Agents Surveillance Report, the incidence rate of Lyme disease per 100,000 people in Japan was 0.008
Lyme Disease Market Outlook
The current preventive landscape for Lyme disease is largely dominated by vaccine-based approaches, with no approved drug-based prophylaxis available. TP-05, an oral systemic formulation of lotilaner, represents a novel market entrant and is believed to be the only non-vaccine, drug-based candidate in development targeting infected tick vectors before they can transmit Borrelia bacteria. Designed to rapidly achieve systemic blood levels of lotilaner, a well-characterized anti-parasitic agent, TP-05 offers on-demand protection and is currently in Phase IIa clinical evaluation. The introduction of such an innovative therapeutic has the potential to reshape the Lyme disease prevention market by addressing unmet needs in populations where vaccination may be unsuitable or unavailable, thereby expanding prevention options and potentially driving market growth in the coming years.
Growth in the broader Lyme disease landscape is also being shaped by rising case numbers and expanded surveillance, which are driving demand for diagnostics, treatments, and prevention tools, fueling market growth across testing, therapeutics, and public health services. The diagnostics market is expanding as well, with demand for more accurate, faster, and higher-volume testing (ELISA, modified two-tier algorithms, PCR, point-of-care assays) pushing investment in new platforms; recent market analyses show multi-billion-dollar global testing markets with mid-single-digit to low-double-digit CAGRs.
Marketed Lyme Disease Drugs
No therapies are currently approved by the US FDA specifically for the treatment of Lyme disease. Instead, treatment relies on antibiotics approved for other bacterial infections that are commonly used off-label to manage the condition, including doxycycline, amoxicillin, and cefuroxime axetil.
Download the Lyme Disease market report for in-depth insights on pipeline and forecast
Emerging Lyme Disease Drugs
The Lyme disease market is expected to evolve with the launch of emerging therapies. Companies worldwide are diligently working to develop novel therapies, achieving considerable success over the years. Key players, such as Valneva/Pfizer (VLA15), Tarsus Pharmaceuticals (TP-05), Moderna (mRNA-1982 and mRNA-1975), and others, are developing therapies for the management of Lyme disease.
- VLA15 – Valneva and Pfizer
VLA15 is an investigational multivalent recombinant protein vaccine targeting six serotypes of Borrelia commonly associated with Lyme disease in the United States and Europe. It acts by inducing antibodies against outer surface protein A (OspA), which is expressed by the bacterium within the tick; blocking OspA prevents transmission to humans. VLA15 is the most advanced Lyme disease vaccine candidate currently in clinical development and is in Phase III development.
Pfizer, in partnership with Valneva, plans to submit a BLA to the FDA and a MAA to the EMA in 2026, pending positive trial outcomes
The vaccine received FDA Fast Track Designation in 2017
- TP-05 – Tarsus Pharmaceuticals
TP-05 is an oral systemic formulation of lotilaner under development for the prevention of Lyme disease, believed to be the only non-vaccine, drug-based preventive therapy in progress that targets and kills infected tick vectors before they can transmit Borrelia bacteria. Designed to rapidly achieve systemic blood levels of lotilaner, a well-characterized anti-parasitic agent, it offers on-demand protection and is currently being assessed in a Phase IIa trial according to the company’s pipeline.
Lyme Disease Drugs Uptake
This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025–2034. The landscape of Lyme disease treatment has experienced a profound transformation with the uptake of novel medicines, with these innovative therapies redefining standards of care.
Conclusion
The Lyme disease market is set for continued evolution through 2034, shaped by rising case numbers, expanded surveillance, and a growing diagnostics market supported by demand for faster, more accurate testing. With no FDA-approved therapies specifically indicated for the condition, current management continues to rely on off-label antibiotics such as doxycycline, amoxicillin, and cefuroxime. However, the emerging pipeline, led by vaccine candidate VLA15 and non-vaccine preventive candidate TP-05, along with Moderna’s mRNA-1982 and mRNA-1975, signals a shift toward more targeted prevention options. As surveillance expands and novel prophylactic and therapeutic approaches progress through clinical development, the Lyme disease market is poised to see meaningful transformation, creating new opportunities for stakeholders while addressing long-standing unmet needs in disease prevention and management.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
